Barinthus Biotherapeutics completed enrollment for two clinical trials: HBV003, a Phase 2b clinical trial of VTP-300 in adults with chronic hepatitis B; and PCA001, a Phase 1 clinical trial of VTP-850 in men with rising prostate-specific antigen after definitive local therapy for prostate cancer. Interim data update for HBV003 is anticipated in Q4. Data update for PCA001 is anticipated in H1 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRNS:
- Barinthus Biotherapeutics initiates Phase 1 clinical trial of VTP-1000
- Barinthus Biotherapeutics Elevates Griffiths to COO
- Barinthus price target lowered to $9.50 from $11 at Alliance Global Partners
- Barinthus Biotherapeutics reports Q2 EPS (43c), consensus (41c)